Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03994874
Other study ID # CQ012019
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 2024
Est. completion date March 2026

Study information

Verified date May 2024
Source Iperboreal Pharma Srl
Contact Arduino Arduini, MD
Phone +41 79 7878312
Email a.arduini@corequest.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).


Description:

The study will include adults HFrEF patients, that despite guidelines directed medical therapy still retain a congestive heart failure (HF) picture. During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change. Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving stable medical therapy according to international guidelines and comprehensive of loop diuretic (furosemide) dose till to 2.5mg/kg/day, without PUF therapy. The PUF ultrafiltration will be performed with a single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours, for 6 months. An independent data safety monitoring board (DSMB) will be convened for this study and will review the results of the trial at regular intervals to protect patients participating in the study. An adaptive interim analysis will be performed when in each group 20 patients have completed 6 months in the study, for analysis of the primary outcome. The purpose of the adaptive interim analysis is to calculate the final study sample size.The DSMB will closely examine the interim primary efficacy results, respecting the confidentiality and integrity of data, to investigate the final sample sizes necessary to complete the study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 84
Est. completion date March 2026
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 yrs - Left ventricular ejection fraction =60% - NYHA Classification of III-IV despite guidelines directed medical therapy - Right ventricular failure due to after load mismatch, addressed by the presence of tricuspid calve regurgitation (= moderate) and by the disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio =0.65, detected with right heart catheterization performed after stable medical therapy according to international guidelines and comprehensive of loop diuretic (equivalent to furosemide oral dose till 2.0 mg/kg/day), coupled with urinary sodium excretion = mEq/L, confirmatory of loop diuretic resistance. - Cava vein enlargement (inner diameter, detected with focused echocardiography, between 1,5 and 2,5 cm, with respiratory collapse <50% or absent due to intravascular fluid overload) - Decreased kidney function addressed by the measurement of glomerular filtration rate (GFR) urea clearance + creatinine clearance/2 (>15 ml/min/1,73 m2) - NT pro-BNP plasma concentration > 1000 pg/ml or BNP plasma concentration > 250 pg/ml - at least one episode of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) in the 6 months befor the study enrollment - An appropriate PUF technique candidate. - Signed informed consent Exclusion Criteria: - Recipients of heart transplantation - Presence of a mechanical circulatory support device; - Hypertrophic obstructive cardiomyopathy; - Uncontrolled hypertension with systolic blood pressure = 160 mmHg - Severe valvular stenosis; - Restrictive cardiomyopathy; - Acute coronary syndrome = 6 months before; - Active myocarditis - Cardiosurgical or Endo-radiological heart procedures = 6 months before - Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT = 6 months before; - Patient with end-stage renal disease, GFR urea clearance + creatinine clearance/2 (<15 ml/min/1,73 m2 GFR) - Any major organ transplant (liver, lung, kidney) - Lung embolism = 6 months before; - Fibrotic lung disease; - Liver Cirrhosis; - Absolute contraindication to peritoneal catheter implantation; - Logistical and or organizational contra-indication to treatment - Active malignancy; - Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later - Female patients of childbearing age who do not use adequate contracteption. - Unwilling and unable to give informed consent; - Enrolment in another clinical trial involving medical or device based interventions. - Hypersensibility to IMP components. - Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and/or prevent the subject from participating in the study procedures and/or potentially afftecting the study quality data.

Study Design


Intervention

Drug:
PolyCore (Polydextrin, L-Carnitine, D-xylitol)
A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.

Locations

Country Name City State
Italy Ospedale Ss. Annunziata Chieti
Italy ASST FBF Sacco Milano
Italy Ospedale Monaldi Napoli

Sponsors (1)

Lead Sponsor Collaborator
Iperboreal Pharma Srl

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite end-point of mortality and worsening patient's condition patient's mortality - or
the need of increasing of =50% the initial daily dose of loop diuretic - or
the hospitalization for infusional therapy with loop diuretic based on the lack of adequate response to maximal dose of oral furosemide (>2.5 mg/kg/day) - or
requiring other methods of treatment [i.e. PUF or hemodialysis], based on persistence of high venous congestion (detected with central venous pressure measurement: >8 mm Hg or dilated inferior cava vein, without respiratory change, measured with focused abdominal echography, and coupled with body weight increase of 1 kg or more in the last 24 hrs.
Up to 7 months from randomization
Secondary 6 min Walking distance Change from the baseline At 3, 6 and 7 months from randomization
Secondary Quality of life tested with Kansas City Cardiomyopathy Questionnaire (KCCQ) Change from the baseline At 3, 6 and 7 months from randomization
Secondary Number of patients with decrease of NT pro-BNP (N-terminal pro brain natriuretic peptide) The number of patients with a decrease in NT pro-BNP level of =25% from baseline At 3, 6 and 7 months from randomization
Secondary Worsening of renal function Estimated Glomerular Filtration Rate (eGFR) =20 ml/min Up to 7 months from randomization
Secondary Cumulative daily dosage of loop diuretic Change over the 6 months of study treatment, Up to 7 months from randomization
Secondary Use of hospital resources The number of days spent in-hospital because of HF exacerbation during the 6 months of study treatment Up to 7 months from randomization
Secondary New York Heart Association (NYHA) class Change from baseline At 3, 6 and 7 months from randomization and during long-term FUs
Secondary Number of patients requiring hospitalization Hospitalization for infusional therapy with loop diuretic Up to 7 months from randomization
Secondary Number of patients increasing of =50% the initial daily dose of loop diuretic Change from baseline Up to 7 months from randomization
Secondary Adverse Events Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory or instrumental test, will be collected, recorded and followed as appropriate. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Terminated NCT05594940 - Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
Recruiting NCT04982081 - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection Phase 1
Completed NCT04394754 - Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure N/A
Active, not recruiting NCT01385176 - Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) N/A
Not yet recruiting NCT05516290 - Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
Completed NCT02885636 - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial Phase 3
Terminated NCT02788656 - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) Phase 4
Terminated NCT02205411 - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation N/A
Completed NCT02252757 - Assess Measurements of Wireless Cardiac Output Device N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Withdrawn NCT00346177 - Stem Cell Study for Patients With Heart Failure Phase 2
Active, not recruiting NCT01058837 - SCD-HeFT 10 Year Follow-up N/A
Completed NCT00957541 - Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device Phase 2